摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

quercetin-3-O-rutinoside | 207671-50-9

中文名称
——
中文别名
——
英文名称
quercetin-3-O-rutinoside
英文别名
rutin trihydrate;rutin;Rutin hydrate;2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one;hydrate
quercetin-3-O-rutinoside化学式
CAS
207671-50-9
化学式
C27H30O16*3H2O
mdl
——
分子量
664.571
InChiKey
PGHSKTKIQIBATG-ZAAWVBGYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    195°C (dec.) (lit.)
  • 溶解度:
    吡啶:可溶50mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    -2.51
  • 重原子数:
    44
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    267
  • 氢给体数:
    11
  • 氢受体数:
    17

SDS

SDS:5c4e3a59df62ae0e67619ff1c8efa3e7
查看

制备方法与用途

生物活性

Rutin(芸香苷,又称槲皮素-3-芸香糖苷、Sophorin)是一种在柑橘等多种植物中被发现的配糖。

体内研究

Rutin 具有改善镉氯化物诱导的大鼠空间记忆丧失和神经细胞凋亡的作用。它通过提高乙酰胆碱水平、抑制 JNK 和 ERK1/2 活性以及激活 mTOR 信号通路来发挥作用。

用途

维生素类药物,能够降低毛细血管的通透性和脆性,并保持及恢复毛细血管的正常弹性。主要用于防治高血压脑溢血、糖尿病视网膜出血和出血性紫癜等疾病,也可用作食品抗氧化剂和着色剂。

反应信息

  • 作为反应物:
    描述:
    quercetin-3-O-rutinosideβ-环糊精乙醇 为溶剂, 反应 24.0h, 生成
    参考文献:
    名称:
    通过与β-环糊精和(2-羟丙基)-β-环糊精络合增强芦丁的溶解性和光稳定性
    摘要:
    芦丁是一种黄酮类化合物,在癌症、糖尿病、高血压和高胆固醇血症等多种慢性疾病的治疗中有着广泛的应用。芦丁的水溶性较差,在药物上的应用受到限制。增强溶解性和稳定性的方法之一是形成包合物。本研究的目的是通过制备β-环糊精(β-CD)和(2-羟丙基)-β-环糊精(HP-β-CD)的包合物来提高芦丁的溶解性、抗氧化活性和光稳定性。使用FT-IR、XRD、1H NMR方法对包合物进行了结构表征。所得结果表明,芦丁与环糊精在乙醇和水 2:3 (v/v) 的混合液中在室温下成功络合 24 h。相溶度研究表明,随着环糊精用量的增加,芦丁的溶解度呈线性增加,即配合物的摩尔比为1:1。芦丁:β-CD 和芦丁:HP-β-CD 复合物的稳定性常数计算值分别为 508.4 和 488.9 M-1。制备包合物后,芦丁的清除能力增强,抗氧化活性得到提高。光稳定性研究表明,与游离芦丁相比,复合芦丁更稳定,并且不受辐射影响。
    DOI:
    10.1007/s10847-016-0638-8
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)<br/>[FR] COMPOSES HETEROCYCLIQUES BLOQUANT LES EFFETS DES PRODUITS TERMINAUX AVANCES DE GLYCATION
    申请人:REDDYS LAB LTD DR
    公开号:WO2005040163A1
    公开(公告)日:2005-05-06
    The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.
    本发明涉及公式(Ia)或(Ib)的新化合物,它们的药学上可接受的盐以及含有它们的药学上可接受的组合物。在上述公式中,公式(Ia)或公式(Ib)中的L代表公式(I)、公式(II)或-(CH2)1-,Q代表公式(III)或公式(IV)。本发明还涉及制备上述新化合物、其药学上可接受的盐和含有它们的药物组合物的方法。本发明还涉及包括治疗由炎症反应引起的病理生理条件的化合物的方法和组合物。具体而言,本发明涉及抑制或阻断组织中糖化蛋白诱导的与信号相关的炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。本发明还涉及作为Perlecan活性和表达调节剂的化合物。具体而言,本发明涉及通过调节肝素硫酸蛋白聚糖(HSPG)如Perlecan来抑制平滑肌细胞增殖的化合物。本发明进一步涉及利用化合物治疗由平滑肌增殖特征的血管闭塞性疾病,如狭窄、再狭窄、新内膜增生和动脉粥样硬化。公式(I)的化合物也可用于治疗和/或预防癌症。癌症类型包括黑色素瘤、前列腺癌、白血病、淋巴瘤、非小细胞肺癌、中枢神经系统癌症、乳腺癌、结肠癌、卵巢癌或肾癌。
  • (METH)ACRYLATE MANUFACTURING METHOD
    申请人:TOAGOSEI CO., LTD
    公开号:US20180118658A1
    公开(公告)日:2018-05-03
    The present invention provides a (meth)acrylate manufacturing method characterized in that when manufacturing a (meth) acrylate by an ester exchange reaction between an alcohol and a monofunctional (meth)acrylate using catalyst A and catalyst B together, contact treatment of the ester exchange reaction product with adsorbent C is performed. Catalyst A: One or more kinds of compounds selected from a group consisting of cyclic tertiary amines with an azabicyclo structure and salts or complexes thereof, amidine and salts or complexes thereof, compounds with a pyridine ring and salts or complexes thereof, phosphines and salts or complexes thereof, and compounds with a tertiary diamine structure and salts or complexes thereof. Catalyst B: One or more kinds of compounds selected from a group consisting of compounds comprising zinc. Adsorbent C: One or more kinds of compounds selected from a group consisting of oxides and hydroxides comprising at least one of magnesium, aluminum and silicon.
    本发明提供了一种(甲基)丙烯酸酯制备方法,其特征在于通过在使用催化剂A和催化剂B一起进行醇和单官能基(甲基)丙烯酸酯之间的酯交换反应制备(甲基)丙烯酸酯时,对酯交换反应产物进行与吸附剂C的接触处理。催化剂A:从含有氮杂双环结构的环状三级胺及其盐或络合物、胺嘧啶及其盐或络合物、含有吡啶环的化合物及其盐或络合物、膦及其盐或络合物、以及含有三级二胺结构的化合物及其盐或络合物中选择的一种或多种化合物。催化剂B:从含锌化合物中选择的一种或多种化合物。吸附剂C:从含有镁、铝和硅中至少一种的氧化物和氢氧化物中选择的一种或多种化合物。
  • MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD
    申请人:TOAGOSEI CO., LTD.
    公开号:US20170204044A1
    公开(公告)日:2017-07-20
    [Problem] The purpose of the present invention is to obtain a multifunctional (meth)acrylate with good yield by an ester exchange reaction of a polyhydric alcohol such as pentaerythritol or dipentaerythritol with a monofunctional (meth)acrylate. [Solution] A multifunctional (meth)acrylate manufacturing method characterized in that when manufacturing a multifunctional (meth)acrylate by an ester exchange reaction of a polyhydric alcohol with a monofunctional (meth)acrylate, catalyst (A) and catalyst (B) are used together. Catalyst (A): One or more kinds of compounds selected from a group consisting of cyclic tertiary amines with an azabicyclo structure or salts or complexes thereof, amidines or salts or complexes thereof, and compounds with a pyridine ring or salts or complexes thereof. Catalyst (B): One or more kinds of compounds selected from a group consisting of zinc-containing compounds.
    [问题] 本发明的目的是通过多元醇(如戊三醇或二戊三醇)与单官能基(甲基)丙烯酸酯的酯交换反应,获得产率高的多功能(甲基)丙烯酸酯。[解决方案] 一种多功能(甲基)丙烯酸酯制备方法,其特征在于,在通过多元醇与单官能基(甲基)丙烯酸酯的酯交换反应制备多功能(甲基)丙烯酸酯时,同时使用催化剂(A)和催化剂(B)。催化剂(A):选自具有氮杂双环结构的环三胺或其盐或络合物、酰胺或其盐或络合物以及吡啶环或其盐或络合物组成的群中的一种或多种化合物。催化剂(B):选自含锌化合物组成的群中的一种或多种化合物。
  • METHOD FOR PRODUCING (METH)ACRYLATE
    申请人:TOAGOSEI CO., LTD.
    公开号:US20180105483A1
    公开(公告)日:2018-04-19
    A method for producing a (meth) acrylate comprises transesterification reaction of an alcohol and a monofunctional (meth) acrylate with catalysts in combination being cyclic tertiary amines having an azabicyclo structure and compounds containing zinc, separating a solid that contains the catalysts from a reaction product containing a (meth) acrylate, and producing a (meth) acrylate by transesterification reaction of an alcohol and a monofunctional (meth) acrylate, while using the recovered solid catalyst.
    生产(甲基)丙烯酸酯的方法包括使用具有氮杂双环结构的环状三级胺和含锌化合物作为催化剂,将醇和单官能团(甲基)丙烯酸酯进行酯交换反应,从含有催化剂的固体中分离出含有(甲基)丙烯酸酯的反应产物,然后通过将醇和单官能团(甲基)丙烯酸酯进行酯交换反应,并使用回收的固体催化剂来生产(甲基)丙烯酸酯。
  • [EN] NOVEL CAFFEINE COCRYSTALS AND THEIR POLYMORPHIC FORMS<br/>[FR] NOUVEAUX CO-CRISTAUX DE CAFÉINE ET LEUR FORMES POLYMORPHES
    申请人:LAURUS LABS PRIVATE LTD
    公开号:WO2017009813A1
    公开(公告)日:2017-01-19
    The present invention relates to novel cocrystals of caffeine and their polymorphic forms.
    本发明涉及咖啡因的新型共晶及其多晶形式。
查看更多